Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | EVP, Chief Strat & Dev Officer | February 28, 2023 | March 02, 2023 |
| MACROGENICS INCMGNX · Entity 6104 | SVP & General Counsel | April 28, 2017 | May 02, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date February 28, 2023 · Filed March 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,645 |
Reported balance
After 2023-02-28 transaction · row 1
1 source rowRow 1 · 2023-02-28 · Tax withholding · Disposed 971 · Balance 86,645 F1: Represents shares of common stock withheld to pay taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to pay taxes.
MACROGENICS INC
Report date April 28, 2017 · Filed May 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,986 |
Reported balance
After 2017-04-28 transaction · row 1
1 source rowRow 1 · 2017-04-28 · Tax withholding · Disposed 1,862 · Balance 16,986 F1: Represents shares of common stock withheld to pay taxes upon vesting of RSU originally granted to the Reporting Person on April 28, 2014. The number of shares withheld was determined on April 28, 2017 based on the closing price of the Company's common stock on that day. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to pay taxes upon vesting of RSU originally granted to the Reporting Person on April 28, 2014. The number of shares withheld was determined on April 28, 2017 based on the closing price of the Company's common stock on that day.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2023 Filed Mar 2, 2023 19:43 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 971 | $12.38 | $12,020.98 |
DisclosureSEC source: 0001367644-23-000058 · wf-form4_167778617847267.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Chief Strat & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,645 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 01:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 845 | $13.71 | $11,584.95 |
DisclosureSEC source: 0001367644-23-000037 · wf-form4_167754740191933.xml · nonDerivative · entry 2 SARAN ATUL · CIK 0001591070 · EVP, Chief Strat & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,616 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 01:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 365 | $14.30 | $5,219.50 |
DisclosureSEC source: 0001367644-23-000037 · wf-form4_167754740191933.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Chief Strat & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,461 F1 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 01:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,051 | $13.25 | $27,175.75 |
DisclosureSEC source: 0001367644-23-000015 · wf-form4_167607930892087.xml · nonDerivative · entry 2 SARAN ATUL · CIK 0001591070 · EVP, Chief Strat & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,826 F2 · shares: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 01:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 95 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-23-000015 · wf-form4_167607930892087.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Chief Strat & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,877 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2022 fiscal year, as certified by the Compensation Committee following the performance period. On February 08, 2023, the final certification date, the Compensation Committee certified the achievement of the 2020-2022 PSUs at a payout factor of 101.67% of target resulting in the actual award of 5,792 shares of common stock, which is in excess of the 5,697 shares previously reported on February 25, 2020. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:45 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 38,664 | $41.38 Strike: $41.38 | $1,599,916.32 |
DisclosureSEC source: 0001367644-22-000041 · wf-form4_164626470277626.xml · derivative · entry 4 SARAN ATUL · CIK 0001591070 · EVP, Chief Strat & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,664 Underlying: Common Stock · 38,664 shares Expires 2029-02-28 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:45 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 16,916 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000041 · wf-form4_164626470277626.xml · nonDerivative · entry 2 SARAN ATUL · CIK 0001591070 · EVP, Chief Strat & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,546 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 23:45 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 31,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000041 · wf-form4_164626470277626.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Chief Strat & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,630 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest either in three equal annual installments beginning on the day prior to the first anniversary of the date of grant (9,667 shares) or on the day prior to the second anniversary date of the grant (21,750 shares), assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:45 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 764 | $39.64 | $30,284.96 |
DisclosureSEC source: 0001367644-22-000041 · wf-form4_164626470277626.xml · nonDerivative · entry 3 SARAN ATUL · CIK 0001591070 · EVP, Chief Strat & Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,782 F3 · security: Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 22:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 857 | $42.47 | $36,396.79 |
DisclosureSEC source: 0001367644-22-000033 · wf-form4_164582752703351.xml · nonDerivative · entry 2 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,213 F1 · security: Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 442 | $42.23 | $18,665.66 |
DisclosureSEC source: 0001367644-22-000033 · wf-form4_164582752703351.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,070 F1 · security: Represents shares of common stock withheld by the Company in exchange for payment of the employee's withholding taxes. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 23:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,084 | $42.23 | $88,007.32 |
DisclosureSEC source: 0001367644-22-000018 · wf-form4_164574668094391.xml · nonDerivative · entry 2 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,512 F2 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 23:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 1,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000018 · wf-form4_164574668094391.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,596 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. On February 22, 2022, the final certification date, the Compensation Committee certified the achievement of the 2019-2021 PSUs at a payout factor of 136.14% of target resulting in the actual award of 6,917 shares of common stock, which is in excess of the 5,081 shares previously reported on February 28, 2019. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 22:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 799 | $97.15 | $77,622.85 |
DisclosureSEC source: 0001367644-21-000043 · wf-form4_161437768971580.xml · nonDerivative · entry 5 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,760 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 22:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 764 | $97.15 | $74,222.60 |
DisclosureSEC source: 0001367644-21-000043 · wf-form4_161437768971580.xml · nonDerivative · entry 4 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,559 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 14,973 | $93.49 Strike: $93.49 | $1,399,825.77 |
DisclosureSEC source: 0001367644-21-000043 · wf-form4_161437768971580.xml · derivative · entry 6 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,973 Underlying: Common Stock · 14,973 shares Expires 2028-02-23 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 887 | $93.49 | $82,925.63 |
DisclosureSEC source: 0001367644-21-000043 · wf-form4_161437768971580.xml · nonDerivative · entry 3 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,323 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 3,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000043 · wf-form4_161437768971580.xml · nonDerivative · entry 2 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,210 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 3,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000043 · wf-form4_161437768971580.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,466 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,430 | $123.45 | $299,983.50 |
DisclosureSEC source: 0001367644-21-000017 · wf-form4_161309660318734.xml · nonDerivative · entry 2 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,722 F2 · security: Represents shares of common stock withheld to pay taxes due upon vesting of the PSUs. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 02:23 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000017 · wf-form4_161309660318734.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,152 F1 · security: Consists of Performance Stock Units ("PSUs") previously granted on February 27, 2018 under the company's stock incentive plan as amended and restated. Each PSU represents the right to receive one share of common stock, which vested at a specified percentage based upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2020 fiscal year, as certified by the Compensation Committee following the performance period. On February 9, 2021, the Compensation Committee certified the achievement of the 2018-2020 PSUs at a payout factor of 150% of target resulting in the actual award of 7,969 shares of common stock, which is in excess of the 5,313 shares previously reported on March 1, 2018. F1 · shares: Consists of Performance Stock Units ("PSUs") previously granted on February 27, 2018 under the company's stock incentive plan as amended and restated. Each PSU represents the right to receive one share of common stock, which vested at a specified percentage based upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2020 fiscal year, as certified by the Compensation Committee following the performance period. On February 9, 2021, the Compensation Committee certified the achievement of the 2018-2020 PSUs at a payout factor of 150% of target resulting in the actual award of 7,969 shares of common stock, which is in excess of the 5,313 shares previously reported on March 1, 2018. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 20:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,303 | $126.96 | $165,428.88 |
DisclosureSEC source: 0001367644-20-000132 · wf-form4_159717910618103.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,496 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 02:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 582 | $59.91 | $34,867.62 |
DisclosureSEC source: 0001367644-20-000021 · wf-form4_158285675699451.xml · nonDerivative · entry 4 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,799 F3 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 02:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 508 | $59.91 | $30,434.28 |
DisclosureSEC source: 0001367644-20-000021 · wf-form4_158285675699451.xml · nonDerivative · entry 3 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,381 F3 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 22,784 | $61.44 Strike: $61.44 | $1,399,848.96 |
DisclosureSEC source: 0001367644-20-000021 · wf-form4_158285675699451.xml · derivative · entry 5 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,105 Underlying: Common Stock · 22,784 shares Expires 2027-02-24 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000021 · wf-form4_158285675699451.xml · nonDerivative · entry 2 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,889 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue for the 2020 - 2022 fiscal years, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:26 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000021 · wf-form4_158285675699451.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,192 F1 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:05 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,287 | $44.47 | $57,232.89 |
DisclosureSEC source: 0001591070-19-000002 · wf-form4_156538113546168.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,495 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,321 | $61.01 Strike: $61.01 | $1,239,784.21 |
DisclosureSEC source: 0001567619-19-005677 · doc1.xml · derivative · entry 4 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,321 Underlying: Common Stock · 20,321 shares Expires 2016-02-25 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005677 · doc1.xml · nonDerivative · entry 3 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,782 F3 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005677 · doc1.xml · nonDerivative · entry 2 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,701 F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:31 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 534 | $61.01 | $32,579.34 |
DisclosureSEC source: 0001567619-19-005677 · doc1.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,620 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,286 | $54.65 | $70,279.90 |
DisclosureSEC source: 0001567619-18-000241 · doc1.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,154 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee stock option (right to buy) · Derivative | 21,253 | $49.64 Strike: $49.64 | $1,054,998.92 |
DisclosureSEC source: 0001140361-18-011296 · doc1.xml · derivative · entry 3 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,253 Underlying: Common Stock · 21,253 shares Expires 2025-02-26 F4 · derivative.exercise_date: Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011296 · doc1.xml · nonDerivative · entry 2 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,440 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011296 · doc1.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,127 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 17:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee stock option (right to buy) · Derivative | 20,083 | $0.00 Strike: $36.09 | $0.00 |
DisclosureSEC source: 0001140361-17-031028 · doc1.xml · derivative · entry 2 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,083 Underlying: Common Stock · 20,083 shares Expires 2024-08-07 F3 · derivative.exercise_date: Vests in three equal installments on August 7, 2018, August 7, 2019 and August 7, 2020. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 17:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 12,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-031028 · doc1.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,814 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| April 28, 2017 Filed May 2, 2017 16:58 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 1,862 | $21.61 | $40,237.82 |
DisclosureSEC source: 0001125345-17-000047 · wf-form4_149374429435733.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,986 F1 · shares: Represents shares of common stock withheld to pay taxes upon vesting of RSU originally granted to the Reporting Person on April 28, 2014. The number of shares withheld was determined on April 28, 2017 based on the closing price of the Company's common stock on that day. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:45 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantCommon Stock · Derivative | 55,000 | $20.53 Strike: $20.53 | $1,129,150.00 |
DisclosureSEC source: 0001125345-17-000034 · wf-form4_148728514328800.xml · derivative · entry 1 SARAN ATUL · CIK 0001591070 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.